Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3911 ARTÍCULOS , VIENDO DEL 1021 AL 1035

Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease

Martinez-Martin P, Rodriguez-Blazquez C, Forjaz MJ, Kurtis MM.

CNS Drugs. 2015 May;29(5):397-413. doi: 10.1007/s40263-015-0247-x.

Antagonistic pleiotropic effects of nitric oxide in the pathophysiology of Parkinson's disease

Tripathy D, Chakraborty J, Mohanakumar KP.

Free Radic Res. 2015;49(9):1129-39. doi: 10.3109/10715762.2015.1045505. Epub 2015 Jun 4.

Olfaction and Aging: A Mini-Review

Attems J, Walker L, Jellinger KA.

Gerontology. 2015;61(6):485-90. doi: 10.1159/000381619. Epub 2015 May 9.

An adverse drug interaction of haloperidol with levodopa

Lucca JM, Ramesh M, Parthasarathi G, Raman R.

Indian J Psychol Med. 2015 Apr-Jun;37(2):220-2. doi: 10.4103/0253-7176.155636.

Adverse reactions to antipsychotics in Parkinson disease: an analysis of the Spanish pharmacovigilance database

Lertxundi U, Ruiz AI, Aspiazu MÁ, Domingo-Echaburu S, García M, Aguirre C, García-Moncó JC.

Clin Neuropharmacol. 2015 May-Jun;38(3):69-84. doi: 10.1097/WNF.0000000000000080.

Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses

Bhidayasiri R, Chaudhuri KR, LeWitt P, Martin A, Boonpang K, van Laar T.

Clin Neuropharmacol. 2015 May-Jun;38(3):89-103. doi: 10.1097/WNF.0000000000000082.

Interferon-alpha caused reversible parkinsonism

Lu CS, Kao WY, Lin JC, Chang PY.

Clin Neuropharmacol. 2015 May-Jun;38(3):119-20. doi: 10.1097/WNF.0000000000000087.

Musical training as an alternative and effective method for neuro-education and neuro-rehabilitation

François C, Grau-Sánchez J, Duarte E, Rodriguez-Fornells A.

Front Psychol. 2015 Apr 28;6:475. doi: 10.3389/fpsyg.2015.00475. eCollection 2015.

Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future

Jenner P.

Transl Neurodegener. 2015 Feb 12;4:3. doi: 10.1186/2047-9158-4-3. eCollection 2015.

How to optimize the treatment of early stage Parkinson's disease

Stocchi F, Vacca L, Radicati FG.

Transl Neurodegener. 2015 Feb 25;4:4. doi: 10.1186/2047-9158-4-4. eCollection 2015.

Thiol redox homeostasis in neurodegenerative disease

McBean GJ, Aslan M, Griffiths HR, Torrão RC.

Redox Biol. 2015 Aug;5:186-194. doi: 10.1016/j.redox.2015.04.004. Epub 2015 Apr 22.

Quantitative assessment of the association between GAK rs1564282 C/T polymorphism and the risk of Parkinson's disease

Ma ZG, He F, Xu J.

J Clin Neurosci. 2015 Jul;22(7):1077-80. doi: 10.1016/j.jocn.2014.12.014. Epub 2015 May 11.

Neuropathobiology of non-motor symptoms in Parkinson disease

Jellinger KA.

J Neural Transm (Vienna). 2015 Oct;122(10):1429-40. doi: 10.1007/s00702-015-1405-5. Epub 2015 May 15.

Prism adaptation in Parkinson disease: comparing reaching to walking and freezers to non-freezers

Nemanich ST, Earhart GM.

Exp Brain Res. 2015 Aug;233(8):2301-10. doi: 10.1007/s00221-015-4299-4. Epub 2015 May 15.

The Role of α-Synuclein and LRRK2 in Tau Phosphorylation

Kawakami F, Ichikawa T.

Parkinsons Dis. 2015;2015:734746. doi: 10.1155/2015/734746. Epub 2015 Apr 21.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias